Hypertrophic Cardiomyopathy
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we investigated whether expression of HCM-associated ANKRD1 mutations affects contraction parameters after gene transfer in engineered heart tissues (EHTs).
|
23572067 |
2013 |
Hypertrophic Cardiomyopathy
|
0.320 |
Biomarker
|
disease |
BEFREE |
CARP abnormalities may be involved in the pathogenesis of HCM.
|
19608031 |
2009 |
Cardiomyopathies
|
0.320 |
Biomarker
|
group |
BEFREE |
Importantly, cardiac ANKRD1 has been shown to be highly induced in various cardiomyopathies and in heart failure, although it is still unclear what impact this may have on the pathophysiology of heart failure.
|
28672880 |
2017 |
Cardiomyopathies
|
0.320 |
GeneticVariation
|
group |
BEFREE |
Increased ANKRD1 levels linked to gain of function mutations have been associated to total anomalous pulmonary venous return and adult cardiomyopathy occurrence in humans.
|
31688894 |
2019 |
Cardiomyopathy, Dilated
|
0.130 |
Biomarker
|
group |
BEFREE |
MLP and CARP are linked to chronic PKCα signalling in dilated cardiomyopathy.
|
27353086 |
2016 |
Cardiomyopathy, Dilated
|
0.130 |
Biomarker
|
group |
BEFREE |
We evaluated ankyrin repeat domain 1 (ANKRD1), the gene encoding cardiac ankyrin repeat protein (CARP), as a novel candidate gene for dilated cardiomyopathy (DCM) through mutation analysis of a cohort of familial or idiopathic DCM patients, based on the hypothesis that inherited dysfunction of mechanical stretch-based signaling is present in a subset of DCM patients.
|
19608030 |
2009 |
Cardiomyopathy, Dilated
|
0.130 |
GeneticVariation
|
group |
BEFREE |
Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy.
|
19525294 |
2009 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Both epinephrine (EPI) and norepinephrine (NE) could directly inhibit breast cancer cell viability, as well as tumor growth <i>in vivo</i> EPI and NE activate the tumor suppressor Hippo signaling pathway, and the suppressive effect of exercise-conditioned serum was found to be mediated through phosphorylation and cytoplasmic retention of YAP and reduced expression of downstream target genes, for example, ANKRD1 and CTGF.
|
28887324 |
2017 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Additionally, our data indicate that the tumor-suppressive effect of ANKRD1 depends on the presence of p53.
|
29179447 |
2017 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
In EGFR-mutant NSCLC patients, ANKRD1 was overexpressed in the tumor after the failure of EGFR-TKI therapy, especially after long-duration EGFR-TKI treatments.
|
30291293 |
2018 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
These findings suggest that ANKRD1, a gene not previously associated with ovarian cancer or with response to chemotherapy, is associated with treatment outcome, and decreasing ANKRD1 expression, or function, is a potential strategy to sensitize tumors to platinum-based drugs.
|
18980987 |
2008 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We wanted to assess the expression of CARPs VIII and XI in these tumors and study their association to different clinicopathological features and tumor-associated CAs II, IX and XII.
|
29792187 |
2018 |
Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
CARP is a potential tumor suppressor in gastric carcinoma and a single-nucleotide polymorphism in CARP gene might increase the risk of gastric carcinoma.
|
24870804 |
2014 |
Heart failure
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The ANKRD1 gene is over-expressed in heart failure in human and animal models.
|
19525294 |
2009 |
Heart failure
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ANKRD1 and RHOU mRNA levels were related with LV function which emphasizes their relevance in HF.
|
24709777 |
2014 |
Heart failure
|
0.040 |
Biomarker
|
disease |
BEFREE |
The upregulation of nuclear CARP expression and positive correlation between cardiac CARP and proANP suggests that CARP may be used as a genetic marker existing in the nuclei in contrast to proANP existing in the cytosol of cardiac cells in heart failure patients.
|
19359327 |
2009 |
Heart failure
|
0.040 |
Biomarker
|
disease |
BEFREE |
Importantly, cardiac ANKRD1 has been shown to be highly induced in various cardiomyopathies and in heart failure, although it is still unclear what impact this may have on the pathophysiology of heart failure.
|
28672880 |
2017 |
Congestive heart failure
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The ANKRD1 gene is over-expressed in heart failure in human and animal models.
|
19525294 |
2009 |
Congestive heart failure
|
0.040 |
Biomarker
|
disease |
BEFREE |
Importantly, cardiac ANKRD1 has been shown to be highly induced in various cardiomyopathies and in heart failure, although it is still unclear what impact this may have on the pathophysiology of heart failure.
|
28672880 |
2017 |
Congestive heart failure
|
0.040 |
Biomarker
|
disease |
BEFREE |
The upregulation of nuclear CARP expression and positive correlation between cardiac CARP and proANP suggests that CARP may be used as a genetic marker existing in the nuclei in contrast to proANP existing in the cytosol of cardiac cells in heart failure patients.
|
19359327 |
2009 |
Congestive heart failure
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ANKRD1 and RHOU mRNA levels were related with LV function which emphasizes their relevance in HF.
|
24709777 |
2014 |
Cardiomyopathy, Familial Idiopathic
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
On the basis of genetic and functional analysis of CARP mutations, we have identified ANKRD1 as a new gene associated with DCM, accounting for approximately 2% of cases.
|
19525294 |
2009 |
Cardiomyopathy, Familial Idiopathic
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
According to our epidemiological data, the prevalence of ANKRD1 mutations seems to be lower than that of its binding partner myopalladin, indicating the clinical significance of myopalladin for the functional integrity of the sarcomeric apparatus and the protection against DCM.
|
22892539 |
2013 |
Cardiomyopathy, Familial Idiopathic
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The ANKRD1 mutations may cause DCM as a result of disruption of the normal cardiac stretch-based signaling.
|
19608030 |
2009 |
Total anomalous pulmonary venous return
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Increased ANKRD1 levels linked to gain of function mutations have been associated to total anomalous pulmonary venous return and adult cardiomyopathy occurrence in humans.
|
31688894 |
2019 |